Key Facts

Invested since 2011
Based in Brandenburg

About the company

A well-rounded life science company, OakLabs’ singular goal is to support scientific companies and institutions with groundbreaking revelations, perhaps most notably in the realm of drug development, companion diagnostics (CDx) and development of IEC 62304 compliant medical device software.

The skilled team of quantum physicists and biochemists at OakLabs have revitalized the process of drug development with a new and efficient approach to patient selection in clinical trials. Their groundbreaking technique entails the use of an innovative algorithm to develop complex biomarker signatures which can accurately predict (non-)responders for specific drugs with superior accuracy. Not only does this lead to success in clinical trials, it can also help to gain market shares in a competitive environment, offering tangible results for continued market success after approval.

Do you want to

know more about this company?

OakLabs in the news

Zum Artikel

Press

8. February 2012

The OakLabs GmbH receives High-Tech Gründerfonds seed funding for intelligent breeding methods